138
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Inhibition of the heme-induced hemolysis of red blood cells by the chlorite-based drug WF10

, , &
Pages 1386-1395 | Received 12 Jul 2016, Accepted 19 Oct 2016, Published online: 23 Nov 2016

References

  • Ferreira A, Balla J, Jeney V, Balla G, Soares MP. A central role for free heme in the pathogenesis of severe malaria: the missing link? J Mol Med 2008;86:1097–1111.
  • Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, et al. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 1996;35:6976–6983.
  • Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004;36:685–697.
  • Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. J Am Med Assoc 2005;293:1653–1662.
  • Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercelotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013;121:1276–1284.
  • Chiabrando D, Vinchi F, Fiorito V, Tolosano E, Haptoglobin and hemopexin in heme detoxification and iron recycling. In: Veas F, ed. Acute phase proteins – regulation and functions of acute phase proteins. Rijeka, Croatia: Intech; 2011:261–288.
  • Bunn HF, Jandl JH. Exchange of heme among hemoglobins and between hemoglobin and albumin. J Biol Chem 1968;243:465–475.
  • Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Eaton JW, Balla G. Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol Nutr Food Res 2005;49:1030–1043.
  • Paoli M, Andeson BF, Baker HM, Morgan WT, Smith A, Baker EN. Crystal structure of hemopexin reveals a novel high-affinity heme site formed between two beta-propeller domains. Nat Struct Biol 1999;6:926–931.
  • Hvidberg V, Maniecki MB, Jacobson C, Hojrup P, Moller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005;106:2572–2579.
  • Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002;100:879–887.
  • Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010;50:323–354.
  • Balla G, Jacob HS, Eaton JW, Belcher JD, Vercelotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 1991;11:1700–1711.
  • Stocker R, Perrella MA. Heme-oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation 2006;114:2178–2189.
  • Figueiredo RT, Fernandez PL, Mourao-Sa DS, Porto BN, Dutra FF, Alves LS, et al. Characterization of heme as activator of toll-like receptor 4. J Biol Chem 2007;282:20221–20229.
  • Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014;123:377–390.
  • Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ, Warren HS. Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol 2012;189:2017–2022.
  • Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett 2005;157:175–188.
  • Schaer D, Vinchi F, Ingoglia G, Tolosano E, Buehler PW. Haptoglobin, hemopexin, and related defense pathways – basic science, clinical perspectives, and drug development. Front Physiol 2014;415:1–13.
  • Schempp H, Reim M, Dornisch K, Elstner E. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10. Drug Res 2001;51:3–11.
  • Jakopitsch C, Spalteholz H, Furtmüller PG, Arnhold J, Obinger C. Mechanism of reaction of horseradish peroxidase with chlorite and chlorine dioxide. J Inorg Biochem 2008;102:108–128.
  • Jakopitsch C, Pirker KF, Flemmig J, Hofbauer S, Schlorke D, Furtmüller PG, et al. Mechanism of reaction of chlorite with mammalian heme peroxidases. J Inorg Biochem 2014;135:10–19.
  • Pichert A, Arnhold J. Interaction of the chlorite-based drug WF10 with hemoglobin, methemoglobin and ferryl hemoglobin. Arch Biochem Biophys 2015;585:82–89.
  • Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, et al. Reduced recurrence of late hemorrahgic radiation cystitis by WF10 therapy in cervical cancer patients. A multicenter, randomized, two-arm, open-label trial. Radiother Oncol 2004;73:179–185.
  • Veerasarn V, Boonnuch W, Kakanaporn C. A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis. Gynecol Oncol 2006;100:179–184.
  • Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, Kühne FW. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection 1998;26:202–207.
  • Yingsakmongkol N, Maraprygsavan P, Sukosit P. Effect of WF10 (Immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial. J Foot Ankle Surg 2011;50:635–640.
  • Yingsakmongkol N. Clinical outcome of WF10 adjunct to standard treatment of diabetic foot ulcers. J Wound Care 2013;22:1–6.
  • Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW. The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glycemic control in diabetes patients with severe foot syndrome. J Clin Transl Endocrinol 2016;4:53–58.
  • Beaven GH, Chen SH, D’Albis A, Gratzer W. A spectroscopic study of the haemin-human-serum-albumin system. Eur J Biochem 1974;41:539–546.
  • McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 2002;3:365–373.
  • Maitra D, Byun J, Andreana PR, Abdulhamid I, Saed GM, Diamond MP, et al. Mechanism of hypochlorous acid-mediated heme destruction and free iron release. Free Radic Biol Med 2011;51:364–373.
  • Nagababu E, Rifkind JM. Formation of fluorescent heme degradation products during the oxidation of hemoglobin by hydrogen peroxide. Biochem Biophys Res Commun 1998;247:592–596.
  • De Villiers KA, Kaschula CH, Egan TJ, Marques HM. Speciation and structure of ferriprotoporphyrin IX in aqueous solution: spectroscopic and diffusion measurements demonstrate dimerization, but not mu-oxo dimer formation. J Biol Inorg Chem 2007;12:101–117.
  • Brown SB, Hatzikonstantinou H, Herries DG. The dimerization of ferrihaems. I. The effect of buffer ions and specific cations on deuteroferrihaem dimerization. Biochim Biophys Acta 1978;539:338–351.
  • Lin T, Maita D, Thundivalappil SR, Riley FE, Hambsch J, Van Marter LJ, et al. Hemopexin in severe inflammation and infection: mouse models and human diseases. Crit Care 2015;166:1–8. 19:article.
  • Smith A. McCulloh. Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. Front Physiol 2015;6:187–20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.